Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Total Liabilities (2022 - 2025)

Historic Total Liabilities for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to $2.3 million.

  • 60 Degrees Pharmaceuticals' Total Liabilities rose 6065.24% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 6065.24%. This contributed to the annual value of $1.8 million for FY2024, which is 3956.68% down from last year.
  • As of Q3 2025, 60 Degrees Pharmaceuticals' Total Liabilities stood at $2.3 million, which was up 6065.24% from $1.8 million recorded in Q2 2025.
  • 60 Degrees Pharmaceuticals' 5-year Total Liabilities high stood at $30.2 million for Q2 2023, and its period low was $1.3 million during Q1 2024.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' median Total Liabilities value was $2.5 million (recorded in 2023), while the average stood at $9.9 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first tumbled by 9547.6% in 2024, then surged by 6065.24% in 2025.
  • Quarter analysis of 4 years shows 60 Degrees Pharmaceuticals' Total Liabilities stood at $25.4 million in 2022, then plummeted by 88.27% to $3.0 million in 2023, then tumbled by 39.57% to $1.8 million in 2024, then rose by 29.82% to $2.3 million in 2025.
  • Its Total Liabilities was $2.3 million in Q3 2025, compared to $1.8 million in Q2 2025 and $1.9 million in Q1 2025.